Apolipoprotein gene polymorphism has an important role in lipid metabolism and in the development of cerebro- and cardio-vascular disease (CCVD), including dementia. Dyslipidemia and hemostatic abnormalities are key risk factors associated with athero-sclerotic events preceding CCVD. The aim of this study was to evaluate the possible relationships of various apolipoprotein-species with hemostatic parameters and cognitive function. Lipid profile, gene polymorphism, coagulation markers, and mini-mental state examination (MMSE) scores were assessed in 109 dys-lipidemic subjects and in 107 healthy control volunteers. Thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels were significantly higher in apolipoprotein-E2 (apoE2) patients when compared to other apoE forms. The apoA5 -1131T>C polymorphism was associated with elevated D-dimer concentration in dyslipidemic TT homozygous individuals. MMSE did not correlate with lipid or coagulation profile. These data suggest that apoE and apoA5 variants have an effect on hemostatic parameters, but they neither influence nor predict cognitive performance in non-demented individuals.
Aldamiz-EchevarriaLSanjurjoPValloAAguirreMPerez-NanclaresGGimenoPRuedaMRuizJIRodriguez-SorianoJ. Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants. Pediatr Nephrol2003; 18: 749–55.
2.
ArikanHKocMSariHTuglularSOzenerCAkogluE. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Renal Fail2007; 29: 713–9.
3.
SagastagoitiaJDSáezYVacasMNarváezILafuenteJPSMolineroEMagroALafitaMSantosMEscobarAIriarteA. Association between inflammation, lipid and hemostatic factors in patients with stable angina. Thromb Res2007; 120: 53–9.
4.
FerreiraCNCarvalhoMGFernandesAPSMLimaLMLoures-ValeAADantasJJankaZPalotásASousaMO. Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio/cerebro-vascular disorders. Neurochem Int2010; 56: 177–82.
5.
GiulianoICBCoutinhoMSSAFreitasSFTPiresMMSZuninoJNRibeiroRQC. Serum lipids in school kids and adolescents from Florianópolis, SC, Brazil – Healthy floripa 2040 study. Arq Bras Cardiol2005; 85: 85–91.
6.
IneuMLManentiECostaJLVMoriguchiE. HDL management: recent advances and perspectives beyond LDL reduction. Arq Bras Cardiol2006; 87: 788–94.
7.
KakafikaAILiberopoulosENKaragiannisAKAthyrosVGMikhailidisDP. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol2006; 4: 175–83.
CarcaillonLGaussemPDucimetièrePGiroudMRitchieKDartiguesJFScarabinPY. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: The three-city cohort study. J Thromb Haemost2009; 7: 1972–8.
13.
BeppuTGil-BernabePBoveda-RuizDD’Alessandro-GabazzaCMatsudaYTodaMMiyakeYShirakiKMurataMMurataTYanoYMorserJGabazzaECTakeiY. High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice. J Thromb Haemost2010; 8: 2514–22.
14.
HenarehLJedeforsCJogestrandTBrodinLAAgewallS. Intima-media thickness of common carotid and brachial arteries and prothrombin fragment 1 + 2 are associated with left ventricular diastolic dysfunction in patients with myocardial infarction. Echocardiography2010; 27: 651–8.
15.
LuszczakJUndasaAGisselMOlszowskaMButenasS. Activated factor XI and tissue factor in aortic stenosis: Links with thrombin generation. Blood Coagul Fibrinolysis2011; 22: 473–9.
16.
QuinnTJGallacherJDearyIJLoweGDOFentonCStottDJ. Association between circulating hemostatic measures and dementia or cognitive impairment: Systematic review and meta-analyzes. J Thromb Haemost2011; 9: 1475–82.
17.
KabaNKFrancisCWMossAJZarebaWOakesDKnoxKLFernandezID. Rainwater DL for the thrombo investigators. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost2004; 2: 718–25.
18.
GagalaJBuraczynskaMMazurkiewiczTKsiazekA. Prevalence of genetic risk factors related with thrombophilia and hypofibrinolysis in patients with osteonecrosis of the femoral head in Poland. BMC Musculoskeletal Disorder2013; 14: 264–264.
19.
StottDJRobertsonMRumleyAWelshPSattarNPackardCJShepherdJTrompetSWestendorpRGJCraenAJMJukemaJWBuckleyBFordILoweGDO. Activation of hemostasis and decline in cognitive function in older people. Arterioscler Thromb Vasc Biol2010; 30: 605–11.
20.
AyCVormittagRDunklerDSimanekRChiriacALDrachJQuehenbergerPWagnerOZielinskiCPabingerI. D-Dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study. J Clin Oncol2009; 27: 4124–9.
21.
FolsomARAleksicNParkESalomaaVJunejaHWuKK. Prospective study of fibrinolytic factors and incident coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol2001; 21: 611–7.
22.
MiyataMIkedaYNakamuraSSasakiTAbeSMinagoeSToriiHLeeSTateishiSKiharaKOhbaIKajiyaSFurushoYHamasakiSTeiC. Kagoshima collaborate trial in metabolic syndrome (KACT-MetS) investigators. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome-The KACT-MetS study. Circ J2012; 76: 843–51.
23.
NarverudIIversenPOAukrustPHalvorsenBUelandTJohansenSGNenseterMSSandsetPMUlvenSMOseLRetterstølKHolvenKB. Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. Thromb Res2013; 131: 178–82.
24.
ChoyPCSiowYLMyminDKarminO. Lipids and atherosclerosis. Biochem Cell Biol2004; 82: 212–24.
25.
YamadaYMatsuoHWaritaSWatanabeSKatoKOguriMYokoiKMetokiNYoshidaHSatohKIchiharaSAoyagiYYasunagaAParkHTanakaMNozawaY. Prediction of genetic risk for dyslipidemia. Genomics2007; 90: 551–8.
26.
BenesPMuzíkJBenedíkJFrélichMElblLVaskuAZnojilVVáchaJ. Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in czech male Caucasians. Mol Genet Metab2000; 69: 137–43.
27.
RahimiZVaisi-RayganiAPourmotabbedT. Association between apolipoprotein ɛ4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in southern Iran. Mol Biol Rep2011; 38: 703–10.
28.
FerreiraCNCarvalhoMGFernandesAPSantosIRRodriguesKFLanaAMQAlmeidaCRLoures-ValeAAGomesKBSousaMO. The polymorphism -1131T>C in apolipoprotein A5 gene is associated with dyslipidemia in Brazilian subjects. Gene2013; 516: 171–5.
29.
LosonczyGVajasATakácsLDzsudzsákEFeketeAMárhofferEKardosLAjznerEHurtadoBFrutosPGBertaABaloghI. Effect of the Gas6 c.834+7G.A polymorphism and the Interaction of known risk factors on AMD pathogenesis in hungarian patients. PLoS ONE2012; 7: e50181–e50181.
30.
GoodmanCGoodmanCSHurJJeyendranRSCoulamC. The association of apoprotein E polymorphisms with recurrent pregnancy loss. Am J Reprod Immunol2009; 61: 34–8.
31.
Al-KhedhairyAA. Apolipoprotein E polymorphism in Saudis. Mol Biol Rep2004; 31: 257–60.
32.
AltamuraCSquittiRPasqualettiPTibuzziFSilvestriniMVentrigliaMCCassettaERossiniMVernieriF. What is the ralationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?Eur J Neurol2007; 14: 679–82.
TakeiNMiyashitaATsukieTAraiHAsadaTImagawaMShojiMHiguchiSUrakamiKKakitaATakahashiHTsujiSKanazawaIIharaYOdaniSKuwanoR. The Japanese Genetic Study consortium for Alzheimer Disease. Genetic association study on in and around the ApoE in late-onset Alzheimer disease in Japanese. Genomics2009; 93: 441–8.
35.
RibaltaJFigueraLFernandez-BallartJVilellaECastroMCMasanaLJovenJ. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem2002; 48: 1597–600.
36.
KlugerMHeerenJMerkelM. Apoprotein A-V: An important regulator of triglyceride metabolism. J Inherit Metab Dis2008; 31: 281–8.
37.
MatsunagaAArishimaHNiimuraHZhangBUeharaYOhwakiKMoritaMHayashidaKSakuK. Strong linkage disequilibrium and association of −1131T>C and c.553G>T of the apolipoprotein A5 genewith hypertriglyceridemia in a Japanese population. Circ J2007; 71: 746–52.
38.
MaaszAKisfaliPJaromiLHorvatovichKSzolnokiZCsongeiVSafranyESipekyCHadaritsFMeleghB. Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke. Circ J2008; 72: 1065–70.
39.
HenarehLJogestrandTHenarehSALJogestrandTAgewallS. Prothrombin fragment 1+2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. Thromb Res2009; 124: 526–30.
40.
GreenowKPearceNJRamjiDP. The key role of apolipoprotein E in atherosclerosis. J Mol Med2005; 83: 329–42.
41.
SmartMCDedoussisGLouizouEYannakouliaMDrenosFPapoutsakisCManiatisNHumphriesSETalmudPJ. APOE, CETP and LPL genes show strong association with lipid levels in Greek children. Nutr Metab Cardiovasc Dis2010; 20: 26–33.
42.
LauerMSFontanarosaPB. Executive summary of the third report of the National Cholesterol Education Program (NCEP) – Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2001; 285: 2486–97.
43.
SpositoACCaramelliBFonsecaFABertolamiMCAfiune NetoASouzaADLottenbergAMChacraAPFaludiAALoures-ValeAACarvalhoACDuncanBGeloneseBPolanczykCRodrigues SobrinhoCRScherrCKarlaCArmaganijanDMoriguchiESaraivaFPichettiGXavierHTChavesHBorgesJLDiamentJGuimarãesJINicolauJCdos SantosJEde LimaJJVieiraJLNovazziJPFaria NetoJRTorresKPPinto LdeABricarelloLBodaneseLCIntrocasoLMalachiasMVIzarMCMagalhãesMESchmidtMIScarteziniMNobreMFoppaMFortiNABerwangerOGebaraOCCoelhoORMaranhãoRCdos Santos FilhoRDCostaRPBarretoSKaiserSIharaSCarvalho TdMartinezTLRelvasWGSalgadoWSociedade Brasileira de Cardiologia. IV Brazilian guideline for dyslipidemia and atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Arq Bras Cardiol2007; 88: 2–19.
44.
FriedewaldWTLevyRIFredrickisonDS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultra. Clin Chem1972; 18: 499–502.
45.
ParraFCAmadoRCLambertucciJRRochaJAntunesCMPenaSD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA2003; 100: 177–82.
46.
FerreiraCNCarvalhoMGReisHJGomesKBSousaMOPalotásA. Hyper-coagulable profile with elevated pro-thrombotic biomarkers and increased cerebro- and cardio-vascular disease risk exist among healthy dyslipidemic women. Curr Neurovasc Res2014; 11: 142–8.
47.
Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects. Clin Chim Acta 2014;433:76–83.
48.
LoweGDORumleyAMcMahonADFordIO’ReillyDSJPackardCJWest of Scotland Coronary Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol2004; 24: 1529–34.
49.
RosénCMattssonNJohanssonPMAndreassonUWallinAHanssonOJohanssonJOLamontJSvenssonJBlennowKZetterbergH. Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases. Front Aging Neurosci2011; 3: 1–1.
50.
Della-MorteDBeechamADongCWangLMcClendonMSGardenerHBlantonSHSaccoRLRundekT. Association between variations in coagulation system genes and carotid plaque. J Neurol Sci2012; 323: 93–8.
51.
MermodJJKruithofEKOAlouaniSQuiquerezALSadoulR. ApoE genotype does not affect plasma tPA and PAI-1 antigen levels. Am J Med Genet1997; 74: 172–5.
52.
SobelBELeeYHPratleyRESchneiderDJ. Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sci2006; 79: 1600–5.
53.
TarnowLStehouwerCDEmeisJJPoirierOCambienFHansenBVParvingHH. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant2000; 15: 625–30.
54.
BattainiFGalliCTremoliEBanfiCMussoniLRiséPCattaneoMGVicentiniL. Very low density lipoprotein mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res1999; 85: 208–17.
55.
RuanXZVargheseZPowisSHMoorheadJF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. Kidney Int2001; 60: 1716–25.
56.
ZhangZPengBGongRGaoLDuJFangDSongYLiYOuG. Apolipoprotein A5 polymorphisms and risk of coronary artery disease: A meta-analysis. BioSci Trends2011; 5: 165–72.
57.
ZhaoTZhaoJ. Association of the apolipoprotein A5 gene -1131 T>C polymorphism with fasting blood lipids: A meta-analysis in 37859 subjects. BMC Med Genet2010; 11: 120–120.
58.
BiNYanSKLiGPYinZNChenBS. A single nucleotide polymorphism -1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol Genet Metab2004; 83: 280–6.
59.
JangYPaikJKHyunYJChaeJSKimJYChoiJRLeeSHShinDJOrdovasJMLeeJH. The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: Association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta2009; 402: 83–7.
60.
GauntTRZabanehDShahSGuyattALadroueCKumariMDrenosFShahTTalmudPJCasasJPLoweGRumleyALawlorDAKivimakiMWhittakerJHingoraniADHumphriesSEDayIN. Gene-centric association signals for haemostasis and thrombosis traits identified with the HumanCVD BeadChip. Thromb Haemost2013; 110: 995–1003.
61.
KimWMMerskeyCDemingQBAdelHNWolinskyHClarksonTBLoflandHB. Hyperlipidemia, Hypercoagulability, and accelerated thrombosis: studies in congenitally hyperlipidemic rats and in rats and monkeys with induced hyperlipidemia. Blood1976; 47: 275–86.
62.
SimpsonHCRMeadeTWStirlingYMannJIChakrabartiRWoolfL. Hypertriglyceridaemia and hypercoagulability. Lancet1983; 9: 786–90.
